Braeburn Inc. v. U.S. Food & Drug Admin.
389 F. Supp. 3d 1
D.C. Cir.2019Background
- Braeburn developed Brixadi (weekly and monthly injectable buprenorphine depots) and received tentative FDA approval on Dec. 21, 2018; final approval for Brixadi Monthly was blocked by the FDA as subject to a three-year exclusivity belonging to Indivior's Sublocade (a monthly buprenorphine depot) under 21 U.S.C. § 355(c)(3)(E)(iii).
- Indivior intervened; Braeburn sued the FDA challenging the Letter Decision that Brixadi Monthly could not be finally approved until Sublocade’s three-year exclusivity expired, alleging statutory error and arbitrary and capricious agency action under the APA.
- The FDA’s exclusivity analysis defined the protected "innovation" as features supported by new clinical investigations essential to approval, and concluded Sublocade’s innovation was a monthly depot delivering buprenorphine to treat moderate-to-severe OUD, which overlapped Brixadi Monthly.
- Braeburn argued the FDA misinterpreted "the conditions of approval" and failed to apply a coherent standard for what counts as the exclusivity-protected innovation (e.g., whether patient population, dosing regimen, or strengths constrain exclusivity).
- The FDA defended its interpretation as consistent with statute and congressional intent; Indivior urged deference and argued Braeburn lacked standing because Sublocade’s possible orphan-drug exclusivity (ODE) or other factors might independently block Brixadi.
- Court disposition: Braeburn’s summary-judgment motion granted; FDA and Indivior denied; decision vacated the Letter Decision and remanded to the FDA to reconsider Brixadi Monthly with deliberate speed; preliminary injunction denied as moot.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Standing | Braeburn: economic harm from FDA Letter Decision is injury, traceable and redressable. | Indivior/FDA: potential ODE or other future actions may be independent causes, making injury speculative. | Braeburn has standing; FDA decision is an actual, redressable cause and speculative alternatives do not defeat standing at summary stage. |
| Meaning of "conditions of approval" under § 355(c)(3)(E)(iii) | "Conditions" should be read narrowly (e.g., indications/labeling or patient populations) so exclusivity protects limited innovations. | FDA: "conditions" covers the innovation supported by new clinical investigations; defers to agency construction. | Phrase is ambiguous; FDA’s starting interpretation (innovation-based) permissible in principle but must be properly and reasonably articulated. |
| Reasonableness of FDA's innovation standard and its application | Braeburn: FDA failed to articulate a coherent standard for defining "innovation" and applied it inconsistently (e.g., compared to Probuphine/Astagraf XL precedents). | FDA/Indivior: agency scientific judgment and precedent support its analysis; differences between products are not "meaningful." | FDA failed to provide an intelligible, principled standard for identifying innovation and applied inconsistent reasoning; decision arbitrary and capricious. |
| Remedy | Braeburn sought vacatur and remand to obtain final approval for Brixadi Monthly. | Indivior sought judgment upholding exclusivity or a stay pending ODE proceedings. | Court vacated the Letter Decision and remanded to FDA for reconsideration with deliberate speed; no preliminary injunction needed. |
Key Cases Cited
- Otsuka Pharm. Co. v. Price, 869 F.3d 987 (D.C. Cir.) (discusses scope of exclusivity under § 355(c)(3)(E)(iii))
- Otsuka Pharm. Co. v. Burwell, 302 F. Supp. 3d 375 (D.D.C.) (interpreting "conditions of approval" issues under exclusivity provisions)
- Depomed, Inc. v. U.S. Dep't of Health & Human Servs., 66 F. Supp. 3d 217 (D.D.C.) (pre-FDARA construction of Orphan Drug Exclusivity and clinical-superiority requirement)
- Kisor v. Wilkie, 139 S. Ct. 2400 (2019) (deference principles for agency interpretations)
- Chevron U.S.A. Inc. v. Natural Resources Defense Council, Inc., 467 U.S. 837 (1984) (two-step framework for reviewing agency statutory interpretations)
- Clapper v. Amnesty Int'l USA, 568 U.S. 398 (2013) (standing and speculative injury inquiry)
- AstraZeneca Pharms. LP v. FDA, 713 F.3d 1134 (D.C. Cir.) (Chevron review of FDA letter decisions)